(Q34662423)

3 August 2017

Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. (English)

1 reference

samarium (153sm) lexidronam

3 August 2017

0 references

1 reference

1 reference

Peter M Anderson

1

1 reference

3 August 2017

Vivek Subbiah

series ordinal

2

1 reference

3 August 2017

Eric Rohren

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

Advances in Experimental Medicine and Biology

3 August 2017

1 reference

3 August 2017

804

1 reference

3 August 2017

291-304

1 reference

Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective

3 August 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Alpha emitter radium-223 and survival in metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

The role of radiation therapy in the treatment of osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Radiotherapy for local control of osteosarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Multimodality treatment of osteosarcoma: radiation in a high-risk cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Cervical spine osteosarcoma treated with carbon-ion radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

The role of radiotherapy in oseosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Stereotactic body radiation therapy for lung metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Samarium for osteoblastic bone metastases and osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Therapeutic radionuclides: biophysical and radiobiologic principles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Molecular pathways: targeted α-particle radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Palliation of Metastatic Bone Pain: Single Fraction versus Multifraction Radiotherapy – A Systematic Review of Randomised Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Palliative radiotherapy trials for bone metastases: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-04843-7_16

10.1007/978-3-319-04843-7_16

31 March 2020

Identifiers

DOI

1 reference

3 August 2017

1 reference